TW202222832A - 抗整聯蛋白β７抗體調配物及裝置 - Google Patents

抗整聯蛋白β７抗體調配物及裝置 Download PDF

Info

Publication number
TW202222832A
TW202222832A TW110127937A TW110127937A TW202222832A TW 202222832 A TW202222832 A TW 202222832A TW 110127937 A TW110127937 A TW 110127937A TW 110127937 A TW110127937 A TW 110127937A TW 202222832 A TW202222832 A TW 202222832A
Authority
TW
Taiwan
Prior art keywords
hvr
formulation
seq
amino acid
acid sequence
Prior art date
Application number
TW110127937A
Other languages
English (en)
Chinese (zh)
Inventor
珍妮佛 波力
梅娜 濤 湯
史瓦蒂 托勒
海倫 泰瑞爾
瑪麗亞姆 阿布候賽因
赫曼特 艾爾馬欽塔
奧黛麗 博魯夫卡
翰廷 丁
希瑟 Ｌ 弗洛雷斯
葛蘭 史考特 吉賽
雷納托 拉瓦內洛
文惠 張
Original Assignee
美商建南德克公司
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建南德克公司, 瑞士商赫孚孟拉羅股份公司 filed Critical 美商建南德克公司
Publication of TW202222832A publication Critical patent/TW202222832A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW110127937A 2020-07-31 2021-07-29 抗整聯蛋白β７抗體調配物及裝置 TW202222832A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
US63/059,427 2020-07-31

Publications (1)

Publication Number Publication Date
TW202222832A true TW202222832A (zh) 2022-06-16

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110127937A TW202222832A (zh) 2020-07-31 2021-07-29 抗整聯蛋白β７抗體調配物及裝置

Country Status (11)

Country Link
EP (1) EP4188958A1 (he)
JP (1) JP2023536158A (he)
KR (1) KR20230041071A (he)
AR (1) AR123085A1 (he)
AU (1) AU2021316017A1 (he)
BR (1) BR112023001734A2 (he)
CA (1) CA3190109A1 (he)
IL (1) IL300133A (he)
MX (1) MX2023001157A (he)
TW (1) TW202222832A (he)
WO (1) WO2022026699A1 (he)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
KR20050085971A (ko) 1995-04-27 2005-08-29 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2002030463A2 (en) 2000-10-12 2002-04-18 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
EP2279004B1 (en) 2008-05-16 2015-01-14 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
MX2011009306A (es) 2009-03-06 2011-10-13 Genentech Inc Formulacion con anticuerpo.
KR102014512B1 (ko) * 2011-05-02 2019-08-26 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
US9132236B2 (en) 2011-06-17 2015-09-15 Shl Group Ab Injection device
AU2012269770B2 (en) 2011-06-17 2015-04-16 Shl Medical Ag Injection device
WO2014160753A1 (en) 2013-03-27 2014-10-02 Genentech, Inc. Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
RU2016136716A (ru) 2014-03-27 2018-04-28 Дженентек, Инк. Способы диагностики и лечения воспалительного заболевания кишечника
JP2018507868A (ja) * 2015-02-26 2018-03-22 ジェネンテック， インコーポレイテッド インテグリンベータ７アンタゴニスト及びクローン病の治療方法
WO2019246455A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
EP4188958A1 (en) 2023-06-07
AU2021316017A1 (en) 2023-02-16
BR112023001734A2 (pt) 2023-02-28
WO2022026699A1 (en) 2022-02-03
JP2023536158A (ja) 2023-08-23
CA3190109A1 (en) 2022-02-03
KR20230041071A (ko) 2023-03-23
IL300133A (he) 2023-03-01
MX2023001157A (es) 2023-02-22
AR123085A1 (es) 2022-10-26

Similar Documents

Publication Publication Date Title
US11534491B2 (en) Methods of treating ankylosing spondylitis using IL-17 antagonists
US20210322546A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
US20210221892A1 (en) Anti-pdl1 antibody formulations
KR101841527B1 (ko) 개선된 고농도 항－ＴＮＦα 항체 액체 제형
KR102259829B1 (ko) 항체 제제
US20230115617A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
JP2021517566A (ja) 汎発性膿疱性乾癬の処置のための抗ｉｌ−３６ｒ抗体の使用
US20210253687A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR20230122034A (ko) 단백질 제형물 및 이의 용도
JP2021147383A (ja) アトピー性皮膚炎及び関連障害を処置するための方法
TW202222832A (zh) 抗整聯蛋白β７抗體調配物及裝置
TW202302640A (zh) 抗tl1a抗體組合物及肺中之治療方法
WO2021259200A1 (zh) 抗ang-2抗体及其用途
TW202246322A (zh) 包含針對類tnf配體1a(tl1a)之人類化抗體之組合物及其用途
US20160244520A1 (en) Compositions and methods for treating psoriatic arthritis
US20180111988A1 (en) Pharmaceutical composition for treating rheumatoid arthritis
WO2023240223A2 (en) Anti-igf-1r antibody compositions
EP3159007A1 (en) Pharmaceutical composition for treating rheumatoid arthritis
CN115297927A (zh) 血浆激肽释放酶抑制剂及其用于治疗儿科遗传性血管性水肿发作的用途